Nice post
There are some excellent opinions on
Nice post
There are some excellent opinions on leronlimab from people with finance backgrounds. I’m a physician and an investment novice. But I work at large hospital with some of the highest number of Covid patients in my state. I’d like to lend my clinical perspective regarding leronlimab and Covid.
1. Covid is out of control. It is much more infectious than the flu. We were initially successful at flattening the curve, but as you can see, the curve is rising again across the country for multiple reasons. We are seeing more and more cases by the day. And while we may be able to slow things down periodically by going into quarantine, we will keep having spikes of this virus for the foreseeable future. Moreover, as we get into the fall and winter most experts predict a massive rise in the virus which could overwhelm our hospital system.
2. A vaccine isn’t coming any time soon. The fastest a vaccine has ever been developed was the mumps vaccine which took 4 years. Granted the entire world and pharmaceutical industry is working toward developing a vaccine but I’m not optimistic that we will have anything for at least another year. I’m also not sure how effective the vaccine will be- not to mention if it will be safe. Think about it. We’ve had influenza for over a hundred years. We spend millions of dollars a year developing a flu vaccine and it’s only partially effective at preventing us from getting sick. How are we going to develop a vaccine that is 100% effective against a virus that we’ve never seen before in 6-12 months? Even if we do, how will we make sure it’s safe and how will we produce enough for the entire country/world?
3. Our current treatments for Covid are next to useless.
We started out using hydroxychloroquine. It has no effect on clinical outcome which has been shown in multiple studies. Dexamethasone is a steroid. We use steroids often in patients with severe respiratory illnesses such as viral or bacterial pneumonia, especially when they develop ARDS- adult respiratory distress syndrome. ARDS is the result of multiple inflammatory mediators that effectively are turned on by an infection- i.e. pneumonia. When ARDS occurs the lungs become stiff and fill up with fluid. Oxygen cannot be effectively be delivered, even with a ventilator. Ultimately this is what kills patients with bad pneumonia and its what kills people with Covid. In Covid we are using dexamethasone but it’s really an act of desperation. It may help decrease inflammation in the lung but only partially. It also is risky to use because it has the side effect of suppressing the immune system further, which can make the infection get worse.
Remdesevir has almost no effect. In the main study quoted by the FDA, it only shortens illness from 15 to 11 days. It has no effect on survival and hasn’t been shown to suppress the virus. It also does nothing to prevent the cytokine storm that leads to ARDS. In my hospital we were one of the early adopters of Remdesevir and I’m just not seeing much of a difference.
4. Leronlimab seems tailor made to help decrease mortality from Covid. Cytokine storm is the main mechanism through which Covid kills patients. Think about a critically ill patient like you would a boulder on the edge of a cliff. Once the boulder gets rolling, the more damage it will cause. Leronlimab blocks inflammatory mediators from coming to the site of infection, effectively stopping the boulder in its tracks. As Dr. Patterson highlighted, it also helps reduce the viral load in the blood and helps restore the immune system so the patient can start to fight the infection on their own.
5. Leronlimab is safe as demonstrated in the HIV data.
6. The mechanism through which leronlimab shuts down inflammation could be useful in the treatment of many other diseases besides Covid.
Sorry for the long post but the more research I do on this drug the more I believe in it. I’m hoping to have it available soon so we can start using it on our patients. I think its going to change the entire course of this pandemic.
9
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...
Continue Reading
Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...
Continue Reading
Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....
Continue Reading
Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...
Continue Reading
Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...
Continue Reading
Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...
Continue Reading
Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...
Continue Reading
Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...
Continue Reading
China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...
Continue Reading
Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...
Continue Reading
Top 5 Most Recently Viewed Articles
MEXC and Aptos Collaboration Recently, MEXC has announced an exciting collaboration with Aptos, creating a series of events centered around Aptos' native token, APT. This partnership offers a total prize pool of an astounding 1.5 million USDT, which is sure to catch the attention of many crypto enthusiasts and traders. Overview of the Events The events are designed to...
Continue Reading
Jim Cramer's Perspective on Shopify's Growth Potential Recently, renowned financial commentator Jim Cramer expressed optimism regarding Shopify Inc. (NASDAQ: SHOP), suggesting that the company is poised for significant growth. Cramer shared these insights on CNBC's "Mad Money", emphasizing that Shopify's innovative capabilities and expanding market share indicate a...
Continue Reading
Citrin Cooperman Expands Its Reach Citrin Cooperman has made significant strides in enhancing its service offerings with the recent announcement of its agreement to acquire the Clearview Group. This acquisition marks a pivotal moment for Citrin Cooperman as it seeks to strengthen its presence in the Mid-Atlantic region. Clearview Group is a well-respected management...
Continue Reading
The Importance of Amazon's Upcoming Earnings Report Shares of tech giant Amazon.com (NASDAQ: AMZN) are currently hovering just above $230 as the company prepares for its first earnings report of the year. This report holds substantial weight as it comes after a period where Amazon has struggled to break through its record highs from last November. The stock is showing...
Continue Reading
Aquablation Therapy Triumphs at EAU 2025: A New Era in BPH Treatment SAN JOSE, Calif. – PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is thrilled to share groundbreaking results from the WATER III trial, an independent study that puts Aquablation therapy at the forefront of treatment for benign prostatic hyperplasia (BPH). At the recent European Association of Urology...
Continue Reading